Lyell Immunopharma (LYEL) EBT Margin (2020 - 2025)
Historic EBT Margin for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to 226580.0%.
- Lyell Immunopharma's EBT Margin fell 955800000.0% to 226580.0% in Q3 2025 from the same period last year, while for Sep 2025 it was 798982.93%, marking a year-over-year decrease of 4959924500.0%. This contributed to the annual value of 548667.21% for FY2024, which is 3767018300.0% down from last year.
- Lyell Immunopharma's EBT Margin amounted to 226580.0% in Q3 2025, which was down 955800000.0% from 548300.0% recorded in Q2 2025.
- Over the past 5 years, Lyell Immunopharma's EBT Margin peaked at 23.42% during Q4 2022, and registered a low of 2139533.33% during Q3 2022.
- Over the past 5 years, Lyell Immunopharma's median EBT Margin value was 209724.0% (recorded in 2023), while the average stood at 448089.51%.
- As far as peak fluctuations go, Lyell Immunopharma's EBT Margin tumbled by 2000000000bps in 2022, and later skyrocketed by 2000000000bps in 2023.
- Quarter analysis of 5 years shows Lyell Immunopharma's EBT Margin stood at 1673.1% in 2021, then skyrocketed by 99bps to 23.42% in 2022, then crashed by -1721920bps to 403261.54% in 2023, then tumbled by -342bps to 1783881.82% in 2024, then surged by 87bps to 226580.0% in 2025.
- Its EBT Margin stands at 226580.0% for Q3 2025, versus 548300.0% for Q2 2025 and 764357.14% for Q1 2025.